Drug General Information (ID: DDI2KYTBXM)
Drug Name			Ondansetron		Drug Info		Pimavanserin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiemetics				Atypical Antipsychotics
Structure

Mechanism of Ondansetron-Pimavanserin Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Ondansetron				Pimavanserin
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Ondansetron and Pimavanserin

Recommended Action
Management		Coadministration of pimavanserin with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.

References
1	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.